Best Neurology Companies in North Carolina, United States
The 45 best Neurology companies in North Carolina, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AskBio.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in North Carolina
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AskBio Developer of AAV technologies for treating genetic and complex disorders | $235M | 71 mo ago | 900 | Jude Samulski Co-Founder & CSO | Acquired | 75 patents AAV-mediated gene therapy vectors for renal and neurological disease treatment | 1 partnership · 1 award |
| 2 | Slate Medicines Developer of therapeutics for the treatment of migraine and other headache disorders 53Funding top 20%Talent bottom 49%Global bottom 48% All 3 signals ▾Fundingtop 20% Talentbottom 49% Globalbottom 48% Funding: Raised $130M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 53/100 | $130M | 6 mo ago | — | Neil Buckley Co-Founder & CEO | Series A | — | — |
| 3 | Arrivo BioVentures Developing biologics and small molecules for conditions that are affected by processes in the Central Nervous… | $94M | 33 mo ago | 11 | Stephen Butts Co-Founder & CEO | Series B | — | — |
| 4 | VTV Therapeutics Developer of small molecules for diabetes, muscle weakness and inflammatory diseases | $49M | 29 mo ago | 22 | Paul Sekhri Chairman | Public | 321 patents Small‑molecule therapeutics for metabolic, hematologic, bone and neurodegenerative diseases. | — |
| 5 | BioDelivery Sciences International Specialty pharmaceutical solutions for pain management and addiction | $40M | 86 mo ago | 188 | Jeffrey Bailey CEO | Acquired | 204 patents Mucoadhesive, abuse‑resistant transmucosal drug delivery systems for opioids and pain therapeutics. | — |
| 6 | T3D Therapeutics Developer of therapeutics for neurodegenerative diseases | $33M | 13 mo ago | 14 | John Didsbury Founder and CEO | Series B | — | — |
| 7 | CeNeRx BioPharma Exploring medicines for the mind, biopharmaceutical analysis, and diet research | $33M | 170 mo ago | — | — | Deadpooled | 32 patents Oral sustained‑release antidepressant formulations and androgen‑targeted cancer therapeutics | — |
| 8 | Argolyn Bioscience Developer of peptide-based drug candidates | $16M | 230 mo ago | — | Nick Ellis CEO | Deadpooled | — | — |
| 9 | Cognosci Developing therapeutics for neurodegenerative and inflammatory diseases with unique anti-inflammatory… | $15M | 132 mo ago | — | Mike Vitek Founder & CEO | Funding Raised | 62 patents Patents concentrated in health & consumer products | — |
| 10 | Aerial BioPharma Developing pain management therapeutics | $11M | 154 mo ago | 1 | Stephen Butts Co-Founder & CEO | Deadpooled | 21 patents Carbamate-based pharmaceutical compounds for treating cataplexy (sleep disorder) | — |
| 11 | NeuroGT Developer of gene therapies for rare neurogenetic diseases | $10M | 11 mo ago | — | Haiyan Fu Founder | Funding Raised | — | — |
| 12 | Evecxia Therapeutics Developing 5-HTP drugs to amplify serotonin for mental illness treatment | $10M | 11 mo ago | 10 | Marc Caron Co-Founder | Series A | — | — |
| 13 | r65 Labs Mobile solutions for making behavioural changes | $8M | 69 mo ago | 7 | Mark Williams CEO | Series A | — | — |
| 14 | Addrenex Pharmaceuticals Holistic wellness platform offering articles on mental health, beauty, and physical well-being | $7M | 229 mo ago | — | Joseph Horacek Founder | Acquired | — | — |
| 15 | Amalgent Developer of therapeutics for pain management | $3M | 24 mo ago | 2 | Sam Tetlow | Funding Raised | — | — |
| 16 | Exodos Life Sciences Topical medications for pain and inflammation | $2M | 150 mo ago | — | — | Deadpooled | — | — |
| 17 | Flag Therapeutics Developer of small molecule therapeutics for difficult-to-treat cancers | $2M | 85 mo ago | 2 | Frank Sorgi President & CEO | Seed | — | — |
| 18 | Curaxis Pharmaceutical Specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer’s… | $2M | 198 mo ago | 2 | — | Deadpooled | — | — |
| 19 | Neuronex Nasal spray formulation of diazepam to treat epilepsy. | $2M | 183 mo ago | — | — | Acqui-Hired | 5 patents Intranasal benzodiazepine drug delivery formulations for rapid CNS therapy | — |
| 20 | Regennova Developer of therapies restoring immune balance after infection or injury | $1M | 18 mo ago | — | Michael Vitek Founder | Funding Raised | 4 patents Antimicrobial peptide therapeutics and agricultural biocidal applications | — |
| 21 | Adaptin Bio Developer of drug delivery platform for brain diseases | $1M | 8 mo ago | — | Michael Roberts Co-Founder & CEO | Public | — | — |
| 22 | Aestas Pharma Developer of diagnostic imaging and therapeutic agents for neurodegenerative diseases | $900K | 14 mo ago | — | Zahed Subhan CEO | Funding Raised | — | — |
| 23 | Impulse Wellness Developer of wearable sensor technology for physiological data and health insights | $675K | 38 mo ago | — | Brady Adcock Co-Founder & Chief Technology Officer | Funding Raised | 3 patents Personalized wearable biosignal monitoring devices for therapeutic feedback | — |
| 24 | Ternalys Developer of therapeutics for cancer treatment | $552K | 17 mo ago | — | Pierpaolo Peruzzi Co-Founder | Funding Raised | — | — |
| 25 | Chaperone Therapeutics Developing therapies for neurodegenerative and rare diseases caused by protein misfolding | $457K | 107 mo ago | — | Maria Sippola-Thiele Founder | Seed | — | — |
| 26 | BrainTrip Manufacturer of a wearable device for detecting behavioral changes | $215K | 75 mo ago | 10 | Maximiliano Romero CEO | Funding Raised | — | — |
| 27 | Encep Heal Early-stage drug development company developing therapeutics for patients with substance use and other mental… | $150K | 84 mo ago | 3 | Aaron Lazarus Co-Founder & CEO | Seed | — | — |
| 28 | Praetego Developer of therapies to treat acute kidney injury, brain injury, and diabetic peripheral neuropathy | $120K | 17 mo ago | 1 | — | Seed | 12 patents Small-molecule therapeutics targeting advanced glycation end-products and neurodegenerative diseases | — |
| 29 | Vital Motion Developer of fibromyalgia pain relief device | $100K | 136 mo ago | 6 | Erik Hiester Co-Founder | Deadpooled | — | — |
Top 12 Neurology companies in North Carolina
#1
Series A · Raleigh, North Carolina · founded 2026$130Mraised▾
Developer of therapeutics for the treatment of migraine and other headache disorders. The company is focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorder
- Feb 2026Series A$130M
#2
Series B · Durham, North Carolina · founded 2013 · 14 employees$33Mraised▾
Developer of therapeutics for neurodegenerative diseases. Its product includes T3D-959, an optimal disease remedial therapeutic for the treatment of Alzheimer's disease which treats multiple defects (pathologies) of AD (beta-amyloid pathway and tau pathway) including a likely ‘trigger’ for the disease, insulin, and IGF-resistance.
- Jul 2025Grant (prize money)$2.5M
- Aug 2023Grant (prize money)$2.3M
- Sep 2022Grant (prize money)$1.5M
- Sep 2022Series B$6M
#3
Funding Raised · Research Triangle Park, North Carolina · founded 2019$10.2Mraised▾
Developer of gene therapies for rare neurogenetic diseases. It focuses on lysosomal storage disorders and other conditions affecting the central nervous system. The company utilizes advanced gene therapy technologies, including AAV gene replacement therapy and antibody cleaver technology, to target the root causes of these diseases. A key aspect of its approach is a commitment to precision and patient-centric care. Development also includes a scale-up AAV manufacturing platform to support internal development and external partnerships.
- Sep 2025Grant (prize money)$3M
- Mar 2025Grant (prize money)$2.3M
- Feb 2025Grant (prize money)$1.8M
- Sep 2024Grant (prize money)$456.4K
#4
Series A · Durham, North Carolina · founded 2013 · 10 employees$9.9Mraised▾
Developing 5-HTP drugs to amplify serotonin for mental illness treatment. The company is dedicated to creating novel therapies for mental illnesses by amplifying natural brain serotonin production. They focus on developing proprietary drug delivery technologies to improve the therapeutic properties of 5-HTP, a natural precursor to serotonin. Their approach aims to address the limitations of current antidepressants by enhancing serotonin neurotransmission more effectively. They are committed to serving patients with mental disorders not adequately helped by existing treatments, using a capital-efficient model to maximize resources for drug development. They seek partnerships to further scientific exploration and development in areas of unmet need, utilizing a data-driven approach with precision medicine to match patients with the right treatment. This is a pharmaceutical and biotech company focused on mental health, drug delivery, and serotonin synthesis amplification.
- Sep 2025Series A$5M
- Sep 2023Series A$2.4M
- Sep 2020Series A$7.4M
#5
Public · Charlotte, North Carolina · founded 2023$1Mraised▾
Developer of drug delivery platform for brain diseases. It offers Brain Bispecific T cell Engager hitchhiking drug delivery platform with a ombination of novel T cell engager and specifically manipulated polyclonal T cells for oncology, central nervous system, autoimmune, and cardiovascular diseases.
- Dec 2025Post IPO$1.7M
- Apr 2025Post IPO$7.7M
- Mar 2024Seed$1M
#6
Series B · Morrisville, North Carolina · founded 2015 · 11 employees$94.2Mraised▾
Arrivo BioVentures is focused primarily on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. Arrivo’s team will source and acquire development candidates in or ready for the early stages of human clinical trials and move the projects through clinical proof-of-concept and the next significant valuation inflection point.
#7
Funding Raised · Durham, North Carolina · founded 2016$899.9Kraised▾
Developer of diagnostic imaging and therapeutic agents for neurodegenerative diseases. The company’s lead candidate Cdk5 PET imaging agent (AP-251) provides a PET imaging tool for the early detection of Alzheimer’s diseases and Parkinson’s disease. Also, has a therapeutic AP-121 for an intranasal delivery platform for Alzheimer’s diseases and Parkinson’s disease.
- May 2025Grant (prize money)$449.9K
- Jul 2021Grant (prize money)$450K
#8
Public · High Point, North Carolina · founded 1999 · 22 employees$49Mraised▾
Developer of small molecules for diabetes, muscle weakness, and inflammatory diseases. Its lead candidate, Azeliragon is for type 1 diabetes. Its drug pipeline includes TTP273 is GLP1R agonist for the treatment of type 2 diabetes and cystic fibrosis, HPP593, a PPARδ agonist for the prevention of muscle weakness; HPP737, a PDE4 inhibitor for Psoriasis, HPP971, a Bach1 inhibitor which is being developed for renal diseases, and others.
#9
Funding Raised · Durham, North Carolina · founded 2021$1.5Mraised▾
Developer of therapies restoring immune balance after infection or injury. The company focuses on developing treatments to address immune dysregulation resulting from various infections and injuries. This approach aims to restore the body's natural ability to heal and combat these conditions. The therapies under development are designed to target specific mechanisms of immune imbalance, offering a novel approach to treatment.
- Feb 2025Grant (prize money)$499.9K
- Apr 2023Grant (prize money)$500K
- Sep 2022Grant (prize money)$499.9K
#10
Acquired · Durham, North Carolina · founded 2001 · 900 employees$235Mraised▾
Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
- Sep 2020Grant (prize money)$2.7M
- Apr 2019PE$235M
- Aug 2014Grant (prize money)$270K
- Sep 2010Grant (prize money)$321K
#11
Funding Raised · Chapel Hill, North Carolina · founded 2021$551.5Kraised▾
Developer of therapeutics for cancer treatment. It offers SAGUARO technology that provides microRNA replacement therapy, which include a lead candidate (TT-003) for the treatment of glioblastoma via intratumoral delivery.
- Mar 2025Grant (prize money)$275.8K
- Sep 2022Grant (prize money)$275.8K
#12
Funding Raised · Greenville, North Carolina · founded 2020 · 2 employees$3Mraised▾
Developer of therapeutics for pain management. The company develops oral combination drugs that reduce the doses required for effective analgesia and minimize side effects to offer oral pain management therapeutics.
- Aug 2024Grant (prize money)$220.7K
- Sep 2023Grant (prize money)$2.6M
- Apr 2022Conventional Debt$200K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
- Boston Scient Neuromodulation865
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers75
- Pacesetter67
- Cyberonics54
- PREC Neuroscience43
- Axonics43
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.